Patent ID: 6960587

Claim:
A compound having a formula wherein R 0 , independently, is selected from the group consisting of halo, C 1-6 alkyl, C 2-6 alkenyl, aryl, heteroaryl, C 3-8 cycloalkyl, C 3-8 heterocycloalkyl, C 1-3 alkylenearyl, C 1-3 alkyleneheteroaryl, Het, C(═O)R a , OC(═O)OR a , C 1-4 alkyleneNR a R b , C 1-4 alkyleneHet, C 1-4 alkyleneC(═O)ORa, C(═O)NR a SO2R b , C(═O)C 1-4 alkyleneHet, C(═O)NRaRb, C(═O)NR a C 1-4 alkyleneOR b , C(═O)NR a C 1-4 alkyleneHet, OR a , OC 1-4 alkyleneC(═O)OR a , OC 1-4 alkyleneNR a R b , OC 1-4 alkyleneHet, OC 1-4 alkyleneOR a , OC 1-4 alkyleneNR a C(═O)OR b , NR a R b , NR a C 1-4 alkyleneNR a R b , NR a C(═O)R b , NR a C(═O)NR a R b , N(SO 2 C 1-4 alkyl) 2 , NR a (SO 2 C 1-4 alkyl), nitro, trifluoromethyl, trifluoromethoxy, cyano, SO 2 NR a R b , SO 2 R a , SOR a , SR a , and OSO 2 CF 3 ; R 1 is selected from the group consisting of hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, haloC 1-6 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkylC 1-3 alkyl, arylC 1-3 alkyl, and heteroarylC 1-3 alkyl; R 2 is selected from the group consisting of an optionally substituted monocyclic aromatic ring selected from the group consisting of benzene, thiophene, furan, and pyridine, and an optionally substituted bicyclic ring wherein the fused ring A is a 5- or 6-membered ring, saturated or partially or fully unsaturated, and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulfur, and nitrogen; R 3 is hydrogen or C 1-6 alkyl, or R 1 and R 3 together form a 3- or 4-membered alkyl or alkenyl chain component of a 5- or 6-membered ring; fused ring B is a 5-, 6-, or 7-membered ring, saturated or partially or fully unsaturated, comprising carbon atoms and optionally one to three heteroatoms selected from oxygen, sulfur, and nitrogen; R a is selected from the group consisting of hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl, heteroaryl, arylC 1-3 alkyl, C 1-3 alkylenearyl, C(═O)OR b , C(═O)N(R b ) 2 , C 1-4 alkyleneN(R b ) 2 , halo, NO 2 , CF 3 , CF 3 O, OR b , OC(═O)R b , OC 1-4 alkyleneC(═O)OR b , C 1-4 alkyleneOC 1-4 alkyleneC(═O)OR b , C(═O)NR b SO 2 R b , C(═O)C 1-4 alkyleneHet, C 2-6 alkenyleneN(R b ) 2 , C(═O)NR b C 1-4 alkyleneOR b , C(═O)NR b C 1-4 alkyleneHet, OC 2-4 alkyleneN(R b ) 2 , OC 1-4 alkyleneCH(OR b )CH 2 N(R b ) 2 , OC 2- alkyleneOR b , OC 2-4 alkyleneNR b C(═O)OR b , N(R b ) 2 , NR b C 1-4 alkyleneN(R b ) 2 , NR b C(═O)R b , NR b C(═O)N(R b ) 2 , N(SO 2 C 1-4 alkyl) 2 , NR b (SO 2 C 1-4 alkyl), SO 2 N(R b ) 2 , OSO 2 trifluoromethyl, C(═O)R b , C 1-3 alkyleneOR b , CN, and C 1-6 alkyleneC(═O)OR b ; R b is selected from the group consisting of hydrogen C 1-6 alkyl, aryl, arylC 1-3 alkyl, C 1- alkylenearyl, heteroaryl, heteroarylC 1-3 alkyl, and C 1-3 alkyleneheteroaryl; q is 0, 1, 2, 3, or 4; or a pharmaceutically acceptable salt or a hydrate thereof.